'I Am Not a Man': Trans-specific Barriers and Facilitators to PrEP Acceptability Among Transgender Women

Overview

Journal Glob Public Health

Publisher Informa Healthcare

Specialty Public Health

Date 2016 Mar 11

PMID 26963756

Citations 145

Authors

Jae M Sevelius

JoAnne Keatley

Nikki Calma

Emily Arnold

Affiliations

Soon will be listed here.

Abstract

The frequent conflation of transgender ('trans') women with 'men who have sex with men (MSM)' in HIV prevention obscures trans women's unique gender identities, social and behavioural vulnerabilities, and their disproportionately high rates of HIV infection. Pre-exposure prophylaxis (PrEP) is an efficacious biomedical HIV prevention approach. However, trans women are underrepresented in PrEP research, and are often aggregated with MSM without consideration for their unique positions within sociocultural contexts. This study examined PrEP acceptability among trans women via three focus groups and nine individual interviews (total N = 30) in San Francisco. While knowledge of PrEP was low, interest was relatively high once participants were informed. Due to past negative healthcare experiences, ability to obtain PrEP from a trans-competent provider was cited as essential to PrEP uptake and adherence. Participants noted that PrEP could address situations in which trans women experience reduced power to negotiate safer sex, including sex work. Trans-specific barriers included lack of trans-inclusive marketing of PrEP, prioritisation of hormone use, and medical mistrust due to transphobia. Findings underscore the importance of disaggregating trans women from MSM in HIV prevention strategies to mitigate disparate risk among this highly vulnerable population.

Citing Articles

Barriers and Facilitators to Integrating Gender-Affirming Care and HIV Prevention/Treatment in Illinois and Missouri: Formative Interviews with Implementation Practitioners.

Zamantakis A, Zapata J, Queiroz A, Donoso V Bull Appl Transgend Stud. 2025; 3(3-4):205-228.

PMID: 39991728 PMC: 11845241.

Facilitators and Barriers to Pre-Exposure Prophylaxis Uptake Willingness for Full-Service Sex Workers: A Social-Ecological Approach.

Ramos S, Du Bois S Sociol Inq. 2025; 94(4):890-909.

PMID: 39831188 PMC: 11737633. DOI: 10.1111/soin.12589.

Intentions to Use PrEP Among a National Sample of Transgender and Gender-Expansive Youth and Emerging Adults: Examining Gender Minority Stress, Substance Use, and Gender Affirmation.

Cluesman S, Gwadz M, Cleland C AIDS Behav. 2025; .

PMID: 39821058 DOI: 10.1007/s10461-025-04613-1.

Facilitators and barriers of HIV pre-exposure prophylaxis use among four key populations in Iran.

Moameri H, Shahrbabaki P, Tavakoli F, Saberi P, Mirzazadeh A, Goudarzi R BMC Health Serv Res. 2024; 24(1):1433.

PMID: 39563358 PMC: 11575091. DOI: 10.1186/s12913-024-11933-w.

Navigating HIV research among criminalized gender minority populations in Uganda: qualitative insights and lessons learned from novice researchers.

Muwanguzi P, Nabunya R, Ngabirano T Int J Equity Health. 2024; 23(1):201.

PMID: 39375702 PMC: 11460160. DOI: 10.1186/s12939-024-02294-1.

References

Sevelius J, Patouhas E, Keatley J, Johnson M . Barriers and facilitators to engagement and retention in care among transgender women living with human immunodeficiency virus. Ann Behav Med. 2013; 47(1):5-16. PMC: 3925767. DOI: 10.1007/s12160-013-9565-8. View

Poteat T, Wirtz A, Radix A, Borquez A, Silva-Santisteban A, Deutsch M . HIV risk and preventive interventions in transgender women sex workers. Lancet. 2014; 385(9964):274-86. PMC: 4320978. DOI: 10.1016/S0140-6736(14)60833-3. View

Sevelius J, Saberi P, Johnson M . Correlates of antiretroviral adherence and viral load among transgender women living with HIV. AIDS Care. 2014; 26(8):976-82. PMC: 4054817. DOI: 10.1080/09540121.2014.896451. View

Grant R, Lama J, Anderson P, McMahan V, Liu A, Vargas L . Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363(27):2587-99. PMC: 3079639. DOI: 10.1056/NEJMoa1011205. View

Bauer G, Hammond R, Travers R, Kaay M, Hohenadel K, Boyce M . "I don't think this is theoretical; this is our lives": how erasure impacts health care for transgender people. J Assoc Nurses AIDS Care. 2009; 20(5):348-61. DOI: 10.1016/j.jana.2009.07.004. View

Wilson E, Jin H, Liu A, Raymond H . Knowledge, Indications and Willingness to Take Pre-Exposure Prophylaxis among Transwomen in San Francisco, 2013. PLoS One. 2015; 10(6):e0128971. PMC: 4454556. DOI: 10.1371/journal.pone.0128971. View

Escudero D, Kerr T, Operario D, Socias M, Sued O, Marshall B . Inclusion of trans women in pre-exposure prophylaxis trials: a review. AIDS Care. 2014; 27(5):637-41. PMC: 4336598. DOI: 10.1080/09540121.2014.986051. View

Golub S, Gamarel K, Rendina H, Surace A, Lelutiu-Weinberger C . From efficacy to effectiveness: facilitators and barriers to PrEP acceptability and motivations for adherence among MSM and transgender women in New York City. AIDS Patient Care STDS. 2013; 27(4):248-54. PMC: 3624632. DOI: 10.1089/apc.2012.0419. View

Yang D, Chariyalertsak C, Wongthanee A, Kawichai S, Yotruean K, Saokhieo P . Acceptability of pre-exposure prophylaxis among men who have sex with men and transgender women in Northern Thailand. PLoS One. 2013; 8(10):e76650. PMC: 3792988. DOI: 10.1371/journal.pone.0076650. View

10.

Sevelius J, Carrico A, Johnson M . Antiretroviral therapy adherence among transgender women living with HIV. J Assoc Nurses AIDS Care. 2010; 21(3):256-64. PMC: 2859994. DOI: 10.1016/j.jana.2010.01.005. View

11.

Machtinger E, Haberer J, Wilson T, Weiss D . Recent trauma is associated with antiretroviral failure and HIV transmission risk behavior among HIV-positive women and female-identified transgenders. AIDS Behav. 2012; 16(8):2160-70. DOI: 10.1007/s10461-012-0158-5. View

12.

Liu A, Cohen S, Follansbee S, Cohan D, Weber S, Sachdev D . Early experiences implementing pre-exposure prophylaxis (PrEP) for HIV prevention in San Francisco. PLoS Med. 2014; 11(3):e1001613. PMC: 3942317. DOI: 10.1371/journal.pmed.1001613. View

13.

Baral S, Poteat T, Stromdahl S, Wirtz A, Guadamuz T, Beyrer C . Worldwide burden of HIV in transgender women: a systematic review and meta-analysis. Lancet Infect Dis. 2012; 13(3):214-22. DOI: 10.1016/S1473-3099(12)70315-8. View

14.

Deutsch M, Glidden D, Sevelius J, Keatley J, McMahan V, Guanira J . HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial. Lancet HIV. 2015; 2(12):e512-9. PMC: 5111857. DOI: 10.1016/S2352-3018(15)00206-4. View

15.

. Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR Morb Mortal Wkly Rep. 2011; 60(3):65-8. View

16.

Herbst J, Jacobs E, Finlayson T, McKleroy V, Neumann M, Crepaz N . Estimating HIV prevalence and risk behaviors of transgender persons in the United States: a systematic review. AIDS Behav. 2007; 12(1):1-17. DOI: 10.1007/s10461-007-9299-3. View

17.

Nadal K, Davidoff K, Fujii-Doe W . Transgender women and the sex work industry: roots in systemic, institutional, and interpersonal discrimination. J Trauma Dissociation. 2013; 15(2):169-83. DOI: 10.1080/15299732.2014.867572. View

18.

Whiteman M, Jeng G, Samarina A, Akatova N, Martirosyan M, Kissin D . Associations of hormonal contraceptive use with measures of HIV disease progression and antiretroviral therapy effectiveness. Contraception. 2015; 93(1):17-24. PMC: 4688178. DOI: 10.1016/j.contraception.2015.07.003. View

19.

Coe A, Moczygemba L, Gatewood S, Osborn R, Matzke G, Goode J . Medication adherence challenges among patients experiencing homelessness in a behavioral health clinic. Res Social Adm Pharm. 2012; 11(3):e110-20. PMC: 3733792. DOI: 10.1016/j.sapharm.2012.11.004. View

20.

Operario D, Soma T, Underhill K . Sex work and HIV status among transgender women: systematic review and meta-analysis. J Acquir Immune Defic Syndr. 2008; 48(1):97-103. DOI: 10.1097/QAI.0b013e31816e3971. View